Agios Presents Results of Pyrukynd (mitapivat) in P-III (ACTIVATE) Study for the Treatment of PK Deficiency at EHA 2022
Shots:
- The P-III (ACTIVATE) study and the ongoing LTEs study evaluated Pyrukynd vs PBO in adults with PK deficiency
- As of the Sept 21, 2021 data cut-off, 35.9% of all patients achieved a normal hemoglobin level once during treatment with Pyrukynd while 83.9% of hemoglobin EPs responders
- Improvements in PK deficiency signs incl. the durability of hemoglobin response, reduction in transfusion burden & need for transfusions secondary to poorly tolerated anemia and acute events, bone mineral density remains stable, improves ineffective erythropoiesis & reduces iron overload. New analysis from the peak registry demonstrates a wide range of comorbidities and complications in PK deficiency patients regardless of genotype
Ref: Globalnewswire | Image: Agios
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
